Impact of donor warm ischemia time on outcomes after donation after cardiac death liver transplantation
David P. Foley – 22 February 2014
Role of protein kinase C isoforms in bile formation and cholestasis
M. Sawkat Anwer – 22 February 2014 – Transhepatic solute transport provides the osmotic driving force for canalicular bile formation. Choleretic and cholestatic agents affect bile formation, in part, by altering plasma membrane localizations of transporters involved in bile formation. These short‐term dynamic changes in transporter location are highly regulated posttranslational events requiring various cellular signaling pathways.
Role of protein kinase C isoforms in bile formation and cholestasis
M. Sawkat Anwer – 22 February 2014 – Transhepatic solute transport provides the osmotic driving force for canalicular bile formation. Choleretic and cholestatic agents affect bile formation, in part, by altering plasma membrane localizations of transporters involved in bile formation. These short‐term dynamic changes in transporter location are highly regulated posttranslational events requiring various cellular signaling pathways.
Carbapenem‐resistant Klebsiella pneumoniae colonization at liver transplantation: A management challenge
Maddalena Giannella, Maria Cristina Morelli, Francesco Cristini, Giorgio Ercolani, Matteo Cescon, Michele Bartoletti, Sara Tedeschi, Eddi Pasqualini, Russell E. Lewis, Antonio Daniele Pinna, Pierluigi Viale – 22 February 2014
Liver transplantation in the management of porphyria
Ashwani K. Singal, Charles Parker, Christine Bowden, Manish Thapar, Lawrence Liu, Brendan M. McGuire – 22 February 2014 – Porphyrias are a group of eight metabolic disorders, each resulting from a mutation that affects an enzyme of the heme biosynthetic pathway. Porphyrias are classified as hepatic or erythropoietic, depending upon the site where the gene defect is predominantly expressed.
Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2–producing k. pneumoniae in liver transplant recipients
Christoph Lübbert, Arne C. Rodloff, Sven Laudi, Philipp Simon, Thilo Busch, Joachim Mössner, Michael Bartels, Udo X. Kaisers – 22 February 2014
Solution to recurrent suprahepatic caval stenosis after liver transplantation: Cardiac surgery after repeated dilatations and stenting
Stefano Salizzoni, Renato Romagnoli, Pietro Rispoli, Paolo Strignano, Roberta Suita, Ezio David, Michele Torre, Mauro Rinaldi – 21 February 2014
Health‐related quality of life: Two decades after liver transplantation
Kara M. Sullivan, David M. Radosevich, John R. Lake – 21 February 2014 – In this study, we describe a cohort of patients who received liver transplants before January 1, 1989 at the University of Minnesota Medical Center (UMMC), and we evaluate the health‐related quality of life (HRQOL) of the survivors of this group. One hundred sixty‐one patients—66 adults and 95 children—received whole deceased donor liver transplants.
Donor‐specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus–infected patients
Jacqueline G. O'Leary, Hugo Kaneku, Linda Jennings, Brian M. Susskind, Paul I. Terasaki, Göran B. Klintmalm – 21 February 2014 – Hepatitis C virus (HCV) fibrosis progression after liver transplantation (LT) is accelerated in comparison with fibrosis progression before transplantation. The vast majority of the risk factors for fibrosis progression after LT are not modifiable.
WNT/β‐catenin signaling and hepatocellular carcinoma
Jack R. Wands, Miran Kim – 20 February 2014